Metallo-β-lactamases (MBLs) are a significant clinical problem because they hydrolyze and
inactivate nearly all β-lactam-containing antibiotics. These 'lifesaving drugs' constitute> 50 …

The β-lactams are the most successful class of antibiotic drugs but they are vulnerable to
inactivation by a growing cadre of β-lactamases that now number more than a thousand …

Modern medicine is threatened by the global rise of antibiotic resistance, especially among
Gram-negative bacteria. Metallo-β-lactamase (MBL) enzymes are a particular concern and …

Resistance to β‐lactam antibacterials is commonly associated with the production of the
serine β‐lactamases (SBLs) and/or metallo‐β‐lactamases (MBLs). Although clinically useful …

The β-lactam antibiotics are essential for the treatment of a wide range of human bacterial
diseases. However, a class of zinc-dependent hydrolases known as the metallo-β …

After more than 80 years of development, β‐lactam drugs have become the most widely
used high‐efficiency, low‐toxic broad‐spectrum antibacterial drugs. However, with the …

The global overuse of antibiotics has led to the emergence of drug-resistant pathogenic
bacteria. Bacteria can combat β-lactams by expressing β-lactamases. Inhibitors of one class …

The worldwide proliferation of life-threatening metallo-β-lactamase (MBL)-producing Gram-
negative bacteria is a serious concern to public health. MBLs are compromising the …

Antimicrobial resistance is one of the major problems in current practical medicine. The
spread of genes coding for resistance determinants among bacteria challenges the use of …

Resistance to β-lactam antibiotics is rapidly growing, substantially due to the spread of
serine-β-lactamases (SBLs) and metallo-β-lactamases (MBLs), which efficiently catalyse β …